ADIPOQ and type 2 diabetes mellitus: Therefore, AMPK, adiponectin downstream signaling has been proposed to be a potential therapeutic target to promote osseointegration in bone-to-implant contact and osseointegration, especially in patients with type 2 diabetes [12].